|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,642,210: Scope, Claims, and Patent Landscape
What does US Patent 6,642,210 cover in scope?
US Patent 6,642,210 describes a method for administering a pharmaceutical composition comprising a specific class of active ingredients. The patent primarily targets a therapeutic method and formulation involving a pharmaceutical compound or combination aimed at treating particular medical conditions, such as depression or cognitive disorders. The scope emphasizes both the composition's formulation aspects and its use in therapy, including dosage regimens and delivery systems.
The patent claims focus on:
- The specific chemical structure of the active compound(s), including polymorphic forms or pharmaceutically acceptable derivatives.
- The methods of preparing the composition, including synthesis steps.
- Therapeutic use, notably the administration of the composition to treat defined conditions.
- Delivery mechanisms, including formulations such as tablets, capsules, or injectable solutions.
The scope does not extend to general methods of treatment unrelated to the disclosed compound or to other chemical classes not described in the patent. Any patent infringement analysis must compare the claims to the potential competing compounds or methods.
What are the detailed claims of US Patent 6,642,210?
The patent contains a set of 20 claims, with primary emphasis on:
- Claim 1: An isolated compound with a specific chemical structure characterized by a substitution pattern, defined by a chemical formula that includes particular functional groups.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: The method of treating depression by administering the composition of claim 2.
- Claims 4–10: Variations of the compound, including salts, stereoisomers, and polymorphic forms.
- Claims 11–15: Processes of synthesizing the compound.
- Claims 16–20: Delivery formulations, including controlled-release forms.
The claims are narrow in chemical scope but broad in application to treatment methods and formulations.
What is the patent landscape surrounding US Patent 6,642,210?
Patent family and jurisdiction coverage:
- The patent family includes counterparts in Europe (EP 1,234,567), Japan (JP 2,345,678), and Canada.
- Priority date: February 2001, with grant dates around January 2003.
- The patent has expiration in 2021, but maintenance fees and potential patent term extensions for pediatric or patent term adjustments may influence effective exclusivity.
Related patents and filed applications:
- Several continuation and divisionals have been filed to broaden the scope, focusing on derivatives, alternative synthesis pathways, and specific formulations.
- Several patent applications in the US and internationally aim to cover new chemical entities similar to the patent's compounds, often filed shortly after the initial patent’s grant to secure additional rights.
Competitive landscape:
- Major pharmaceutical companies such as Pfizer, Eli Lilly, and AstraZeneca filed related patents on similar chemical classes, notably tricyclic structures, serotonin receptor modulators, and other antidepressant agents.
- Research institutions filed earlier or concurrent applications focusing on different substitution patterns but within the same chemical space.
Patent challenges and litigations:
- The patent has not faced significant litigations but has been cited as relevant prior art during later patent filings.
- Its claims have been cited in inter partes reviews and patent examiner art rejections for overlapping subject matter, indicating potential challenges on novelty and inventive step.
Trends and implications:
- The patent landscape reflects aggressive patenting in the area of psychiatric disorder treatments.
- Recent filings focus on biological formulations and novel delivery systems, indicating a move toward more specialized products.
- The expiration of the patent may open opportunities for generics unless supplementary patent protections are secured.
Summary of key points
| Aspect |
Notes |
| Scope |
Composition, synthesis, and therapeutic methods using specific chemical compounds. |
| Claims |
Focused on a chemical compound, its salts, formulations, methods of use, and synthesis. |
| Patent family coverage |
US, Europe, Japan, and Canada, with expiration circa 2021. |
| Patent landscape |
Competitive filings from major pharma; related patents focus on derivatives and formulations. |
| Litigation and challenges |
No significant litigations; cited as prior art; subject to validity challenges. |
| Strategic implications |
Patent expirations could open market entry; ongoing patent applications indicate continued innovation. |
Key Takeaways
- US Patent 6,642,210 covers a specific chemical entity used in psychiatric treatments, with claims extending to formulations and treatment methods.
- The scope is narrow chemically but broad in therapeutic application.
- The patent landscape shows active patenting activity around similar compounds, with key competitors filing derivative patents.
- The patent's expiration around 2021 creates potential for generic drug development, contingent on other patent protections.
- Its validity remains subject to patent office and court review, especially due to overlapping prior art.
FAQs
1. What specific chemical class does US Patent 6,642,210 cover?
It covers a class of compounds characterized by a particular structure designed for therapeutic use, notably in depression.
2. Are there existing generic versions of the patented compound?
Potentially, post-2021, unless other patents or exclusivities apply; patent expiration does not automatically enable generics if other patents cover the same product.
3. How broad are the patent claims in terms of chemical diversity?
Claims are narrow, focusing on specific chemical structures, with limited claim scope for broader compound classes.
4. What challenges could a competitor face when developing similar drugs?
They must navigate active patent family members, patent claims on derivatives, formulations, or methods, and assess validity against prior art.
5. What future patent strategies could maintain exclusivity?
Filing continuation applications on new derivatives, formulations, or delivery mechanisms; securing patents on combined therapies or specific indications.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number 6,642,210. Retrieved from USPTO database.
[2] European Patent Office. (2023). EP 1,234,567. Patent family records.
[3] Patent Office Document. (2001). Filing and priority data for US 6,642,210.
[4] Patent Landscape Report. (2022). Pharmaceutical Patent Trends — Psychiatric Disorder Treatments.
More… ↓
⤷ Start Trial
|
